SET7/9 EndMT Use for diagnosing or treating EndMT-related diseases using SET7/9

The present invention relates to a use for diagnosis and treatment of diseases related to endothelial-mesenchymal transition (EndMT) using SET7/9. According to the present inventors, it is confirmed that simultaneous treatment of TGF-β2 and IL-1β is a strong inducing condition for EndMT, that methyl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KOOK YUNJIN, KIM JONGMIN, YUN EUNSIK, LEE ARAM
Format:	Patent
Sprache:	eng ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a use for diagnosis and treatment of diseases related to endothelial-mesenchymal transition (EndMT) using SET7/9. According to the present inventors, it is confirmed that simultaneous treatment of TGF-β2 and IL-1β is a strong inducing condition for EndMT, that methyltransferase SET7/9 is an important epigenetic factor in a process of inducing EndMT, that SET7/9 inhibition inhibits the EndMT by regulating fibrogenic signaling. In addition, it is found that vascular endothelial cell dysfunction caused by the EndMT is restored by the SET7/9 inhibition, and that the EndMT is closely related to pulmonary vascular diseases. The present invention provides a biomarker composition for diagnosing diseases related to EndMT, which contains the methyltransferase SET7/9 protein or a gene encoding the same as an active ingredient. 본 발명은 SET7/9을 이용한 내피간엽이행(endothelial-mesenchymal transition; EndMT) 관련 질환 진단 및 치료 용도에 관한 것으로서, 본 발명자들은 TGF-β2와 IL-1β의 동시처리는 강력한 내피간엽이행의 유도조건이고, 메틸기전이효소 SET7/9은 내피간엽이행 유도 과정의 중요한 후성유전인자이며, SET7/9 억제는 섬유화 신호전달을 조절하여 내피간엽이행을 억제한다는 것을 확인하였다. 또한, SET7/9 억제는 내피간엽이행에 의한 혈관내피세포 기능장애를 회복시켰으며, 내피간엽이행은 폐혈관질환과 밀접한 연관성이 있다는 것을 밝혀냈다.